CERS
Cerus
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 2
Sell signal 0
consensus rating "Buy"
Revenue Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About CERS
Cerus Corporation
A company that develops blood safety systems to inactivate blood-borne pathgens in components intended for transfusion
Healthcare Equipment and Supplies
Invalid Date
01/30/1997
NASDAQ Stock Exchange
281
12-31
Common stock
1220 Concord Avenue, Suite 600, Concord, California 94520
--
Cerus Corporation, founded in California in 1991 and re-incorporated in Delaware in 1996. The Company is a biomedical products company focused on developing and commercializing the INTERCEPT blood system to enhance blood safety. The Company's INTERCEPT blood system is designed to work with blood components and certain of their derivatives: platelets, plasma, red blood cells and the production of INTERCEPT fibrinogen complex, or IFC, as well as pathogen-reducing plasma, cryoprecipitate reduction.
Company Financials
EPS
CERS has released its 2024 Q4 earnings. EPS was reported at -0.01, versus the expected -0.01, meeting expectations. The chart below visualizes how CERS has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
CERS has released its 2024 Q4 earnings report, with revenue of 56.75M, reflecting a YoY change of 6.39%, and net profit of -2.56M, showing a YoY change of -84.45%. The Sankey diagram below clearly presents CERS’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
